Literature DB >> 26793345

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis treatment.

Fei-Shen Lin1, Mei-Ying Wu1, Wen-Jun Tu1, Hong-Qiu Pan1, Jian Zheng1, Jun-Wei Shi1, Zhong-Ting Fei1, Rui-Mei Zhang1, Wei-Guo Yan1, Ming-Qun Shang1, Qiang Zheng1, Meng-Jie Wang1, Xia Zhang1.   

Abstract

BACKGROUND: To investigate the prevalence of and risk factors for leukopenia in tuberculosis patients and the impact of anti-tuberculosis regimens on the occurrence of leukopenia in newly treated tuberculosis patients.
METHODS: A total of 1,904 tuberculosis patients were included in the study. A cross-sectional survey of the prevalence of leukopenia was initially conducted, and then factors influencing leukopenia were identified using Logistic regression analysis. Non-treatment factors influencing peripheral blood leukocyte counts were analyzed using univariate COX proportional hazards models. Covariate analysis was used to assess the independent effect of different anti-tuberculosis regimens on peripheral blood leukocyte counts.
RESULTS: Being female, advanced age and longer duration of previous anti-tuberculosis treatment (>6 month) were risk factors for leukopenia in tuberculosis patients, while secondary pulmonary tuberculosis, higher body mass index (BMI: 24-27.9 kg/m(2)), and higher degree of education (senior high school or above) were protective factors. Gender, vegetable consumption, drinking, pulmonary infection, other chronic diseases, and use of antibiotics were significantly associated with the development of leukopenia in patients on anti-tuberculosis treatment. In tuberculosis patients treated with anti-tuberculosis regimens not containing antibiotics, peripheral blood leukocyte levels gradually declined with the prolongation of treatment duration. In tuberculosis patients treated with anti-tuberculosis regimens containing antibiotics, peripheral blood leukocyte levels showed a declining trend.
CONCLUSIONS: Female patients, patients at advanced age and recurrent tuberculosis patients having longer previous anti-tuberculosis treatment are high-risk populations for leukopenia. Attention should be paid to the influence of vegetable consumption and drinking, co-morbidities and use of antibiotics during anti-tuberculosis treatment.

Entities:  

Keywords:  Tuberculosis; anti-tuberculosis treatment; leukopenia; risk factors

Year:  2015        PMID: 26793345      PMCID: PMC4703664          DOI: 10.3978/j.issn.2072-1439.2015.12.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  9 in total

1.  Leukopenia during treatment with first-line anti-tuberculosis medication.

Authors:  Sei Won Lee; Sang Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  Respiration       Date:  2004-05-28       Impact factor: 3.580

2.  [Acute interstitial nephritis due to rifampicin].

Authors:  Alfredo Jover-Sáenz; José Manuel Porcel-Pérez; Ana Belén Madroñero-Vuelta; Silvia Bielsa-Martín
Journal:  Enferm Infecc Microbiol Clin       Date:  2006-01       Impact factor: 1.731

3.  Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis.

Authors:  V V Banu Rekha; T Santha; M S Jawahar
Journal:  J Assoc Physicians India       Date:  2005-09

Review 4.  Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features.

Authors:  A S De Vriese; D L Robbrecht; R C Vanholder; D P Vogelaers; N H Lameire
Journal:  Am J Kidney Dis       Date:  1998-01       Impact factor: 8.860

5.  [Pulmonary mycobacterioses--frequency of occurrence, clinical spectrum and predisposing factors].

Authors:  Małgorzata Czajkowska; Ewa Augustynowicz-Kopeć; Zofia Zwolska; Iwona Bestry; Magdalena Martusewicz-Boros; Małgorzata Marzinek; Elzbieta Radzikowska; Paweł Remiszewski; Barbara Roszkowska-Sliz; Janusz Szopiński; Jolanta Załeska; Jacek Zych; Ewa Rowińska-Zakrzewska
Journal:  Pneumonol Alergol Pol       Date:  2002

6.  Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota.

Authors:  Erik C von Rosenvinge; Yang Song; James R White; Cynthia Maddox; Thomas Blanchard; W Florian Fricke
Journal:  ISME J       Date:  2013-03-07       Impact factor: 10.302

7.  [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].

Authors:  Naohiro Nagayama; Yuichiro Shishido; Kimihiko Masuda; Motoo Baba; Atsuhisa Tamura; Hideaki Nagai; Shinobu Akagawa; Yoshiko Kawabe; Kazuko Machida; Atsuyuki Kurashima; Hikotaro Komatsu; Hideki Yotsumoto
Journal:  Kekkaku       Date:  2004-05

8.  The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study).

Authors:  P Cahn; K Ruxrungtham; B Gazzard; R S Diaz; A Gori; D P Kotler; A Vriesema; N A Georgiou; J Garssen; M Clerici; J M A Lange
Journal:  Clin Infect Dis       Date:  2013-03-19       Impact factor: 9.079

9.  Micronutrient supplementation and T cell-mediated immune responses in patients with tuberculosis in Tanzania.

Authors:  K Kawai; S N Meydani; W Urassa; D Wu; F M Mugusi; E Saathoff; R J Bosch; E Villamor; D Spiegelman; W W Fawzi
Journal:  Epidemiol Infect       Date:  2013-10-07       Impact factor: 4.434

  9 in total
  2 in total

1.  Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.

Authors:  Miaomiao Yang; Hongqiu Pan; Lihuan Lu; Xiaomin He; Hongbo Chen; Bilin Tao; Wenpei Liu; Honggang Yi; Shaowen Tang
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

2.  Tuberculosis Infection in Chinese Patients with Giant Cell Arteritis.

Authors:  Yun Zhang; Dongmei Wang; Yue Yin; Yu Wang; Hongwei Fan; Wen Zhang; Xuejun Zeng
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.